David Kirske - 17 Jun 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
EVP, Chief Financial Officer
Signature
David Kirske
Issuer symbol
N/A
Transactions as of
17 Jun 2022
Net transactions value
-$197,505
Form type
4
Filing time
17 Jun 2022, 16:57:44 UTC
Previous filing
16 Jun 2022
Next filing
20 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $10,000 +10,000 +135% $1.00 17,397 17 Jun 2022 Direct
transaction CTIC common stock Sale $60,000 -10,000 -57% $6.00 7,397 17 Jun 2022 Direct F1
transaction CTIC common stock Options Exercise $165,000 +50,000 +676% $3.30 57,397 17 Jun 2022 Direct
transaction CTIC common stock Sale $312,505 -50,000 -87% $6.25 7,397 17 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -10,000 -2.9% $0.000000 340,000 17 Jun 2022 Common Stock 10,000 $1.00 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -50,000 -25% $0.000000 150,000 17 Jun 2022 Common Stock 50,000 $3.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
F2 One sixth of the shares underlying the option vested on 9/11/2020 and semi-annually thereafter until all the underlying shares will be fully vested on 3/11/2023.
F3 One sixth of the shares underlying the option vested on 9/10/2021 and semi-annually thereafter until all the underlying shares will be fully vested on 3/10/2024.